Pancragen (KEDW): experimental peptide for pancreas health
A synthetic four-building-block peptide developed in Russia, proposed to help restore normal function in aging pancreatic tissue; experimental, not an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Pancragen is a synthetic four-amino-acid peptide (Lys-Glu-Asp-Trp, abbreviated KEDW) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the Khavinson bioregulator family — short synthetic peptides proposed to restore tissue-specific gene expression in aging — and is the chemically defined synthetic counterpart to Suprefort, a peptide complex prepared from animal pancreatic tissue. The proposed target is pancreatic tissue, particularly the insulin-producing beta cells and the enzyme-secreting acinar cells.
A note on the sequence abbreviation: the peptide is sometimes referred to as "KEDP" in titles and catalog entries (including the platform title), but the fourth residue is consistently identified as tryptophan (Trp, W) in all body text and published research, giving Lys-Glu-Asp-Trp (KEDW). This card follows the consistent sequence description; the title discrepancy is preserved as a known flag.
Among Khavinson catalog entries, Pancragen is relatively well-characterized: eight PubMed-indexed publications span one small human clinical study, primate experiments, rodent pharmacology, and in vitro cell-culture work. The entire evidence base originates from the Khavinson research program at a single institution; no independent laboratory has reproduced the core findings.
History
Pancragen was developed within Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology, part of the same research effort that produced short peptides targeting brain, thymus, pineal gland, and cartilage tissue. The natural-extract predecessor in the pancreatic lineage is Suprefort, a peptide complex prepared from animal pancreatic tissue. Pancragen (Lys-Glu-Asp-Trp) was synthesized as a chemically defined short-peptide counterpart, based on the hypothesis that a tetrapeptide retains the pancreas-specific regulatory effects of the larger natural preparation in a more standardized form. Published research spans biological activity characterization (Khavinson and colleagues 2011), cell-differentiation studies in aged pancreatic cultures (Khavinson and colleagues 2013), diabetic rat pharmacology (Khavinson and colleagues 2007), and primate studies in aged rhesus monkeys (Khavinson and colleagues 2015, 2017), along with one published human study in elderly type 2 diabetes patients (Khavinson and colleagues 2012).
What it does
Pancragen is studied primarily for its effects on pancreatic function in aging. In a small human study of 33 elderly patients with type 2 diabetes, Khavinson and colleagues (2012) reported reduced fasting glucose, improved glucose tolerance, and reduced insulin resistance following treatment; the study also noted that nocturnal melatonin production was reduced approximately 70% in diabetic patients. In aged rhesus monkeys, two primate studies (Khavinson and colleagues 2015, 2017) showed improved glucose clearance and normalized insulin and C-peptide responses; the 2017 study reported that Pancragen outperformed glimepiride in normalizing insulin secretion in aged primates. In diabetic rat models, oral administration produced hypoglycemic effects and injection normalized endothelial adhesion in mesenteric capillaries (Khavinson and colleagues 2007), suggesting both metabolic and vascular signals.
In cell culture, the peptide enhanced expression of pancreatic transcription factors and differentiation markers in aged pancreatic cultures (Khavinson and colleagues 2013), with effects more pronounced in aged than in young tissue.
Evidence
- Human: One published study of 33 elderly patients with type 2 diabetes (Khavinson and colleagues 2012) reported reduced fasting glucose, improved glucose tolerance, and reduced insulin resistance. No Western clinical trials are indexed on ClinicalTrials.gov for Pancragen or its synonyms. The methodology transparency of the published study — blinding, randomization, and control-group specification — is limited.
- Animal: Two primate studies in aged rhesus monkeys (Khavinson and colleagues 2015, 2017) demonstrated improved glucose clearance and normalized insulin and C-peptide responses, with effects persisting three weeks post-treatment; the 2017 study showed superiority over glimepiride on insulin normalization. Diabetic rat data (Khavinson and colleagues 2007) showed hypoglycemic effects with oral administration and normalization of endothelial adhesion with injection.
- In vitro: Aged pancreatic cell cultures showed upregulation of transcription factors PDX1, NGN3, PAX6, FOXA2, NKX2-2, NKX6.1, and PAX4, enhanced expression of MMP2, MMP9, serotonin, and CD79alpha, and reduced apoptosis markers (Khavinson and colleagues 2013). Effects were more pronounced in aged compared to younger tissue.
Replication caveat: All published evidence originates from the Khavinson research program at a single institution. No independent Western laboratory has reproduced the key human or primate findings under modern controlled-trial standards.
Myths and misconceptions
- "Pancragen can replace prescribed diabetes medication" — It cannot. The available evidence is a single small Russian study (n=33) and primate data from one program. It does not establish Pancragen as a stand-alone treatment for type 2 diabetes, and discontinuing prescribed medication in favour of Pancragen risks serious glycaemic events.
- "Pancragen has been proven superior to standard diabetes medications" — It has not. The primate-study comparison with glimepiride is a single small preclinical result from the originating program; it is not equivalent to a head-to-head human clinical trial. Standard diabetes medications have decades of large-scale trial evidence and regulatory pharmacovigilance that Pancragen does not.
- "Russian dietary-complex registration means Pancragen is approved as a diabetes medicine" — Russian Khavinson-affiliated capsule products are marketed as dietary peptide complexes, not as registered pharmaceuticals for diabetes management. This is a different regulatory category with lower evidence requirements than prescription-medicine approval and is not equivalent to Western drug approval.
- "Vladimir Khavinson won the Nobel Prize, validating the Pancragen claims" — He did not. Persistent online attributions to a Nobel Prize are inaccurate. The Khavinson program has published extensively, but the body of work has not received that recognition and core findings have not been independently replicated in Western laboratories.
Known effects
- Reduced fasting glucose and improved insulin resistance in elderly T2D patients — Human, single small Russian study (n=33); preliminary
- Improved glucose clearance and normalized insulin/C-peptide in aged primates — Preclinical (rhesus monkey); two studies from same program
- Outperformed glimepiride on insulin normalization in aged primates — Preclinical (rhesus monkey); one study from originating program
- Hypoglycaemic effects and normalized endothelial adhesion in diabetic rats — Preclinical (rodent); oral and injection routes studied
- Upregulation of pancreatic transcription factors in aged cell cultures — In vitro; effects more pronounced in aged tissue; not independently validated in vivo
Safety signals
No adverse effects were reported in the available human study (n=33) or primate studies, though the sample size and surveillance quality are limited. Mild injection-site reactions are noted as possible for injectable forms.
The most clinically significant theoretical concern is hypoglycaemia risk in combination with insulin, sulfonylureas (including glimepiride, glyburide, glipizide), or meglitinides: Pancragen's reported glucose-lowering and insulin-sensitizing effects could potentiate these agents in uncoordinated combination. No formal drug interaction studies meeting Western standards have been published. Concurrent use with metformin, GLP-1 agonists, SGLT2 inhibitors, or DPP-4 inhibitors has not been studied.
A theoretical concern is noted in the source literature for agents proposed to stimulate pancreatic cell proliferation in contexts of active or recent-history pancreatic malignancy. Long-term safety with cumulative repeated courses, including any effects on pancreatic cell proliferation, has not been characterized. No reproductive toxicology or pediatric safety data are available.
Regulatory status
- US (FDA): Not approved for any indication. Not recognized as a dietary supplement ingredient. Not on the FDA list of peptides eligible for 503A compounding. Injectable forms are sold via research-chemical suppliers not authorized for human use.
- EU (EMA): Not approved.
- Canada (Health Canada): Not approved.
- UK (MHRA): Not approved.
- Russia / CIS: Marketed as dietary peptide complexes (e.g., Peptides.ru brands) — not as registered pharmaceuticals for diabetes management. This is a different regulatory category with lower evidence requirements than prescription-medicine approval.
- WADA: Not specifically named on the Prohibited List. As an unapproved substance in most WADA-code jurisdictions, the S0 catch-all category likely applies to injectable forms. Athletes subject to the WADA code should treat injectable Pancragen accordingly.
Mechanism
Pancragen (Lys-Glu-Asp-Trp) is proposed to exert its effects by binding directly to DNA along the major groove, forming stable peptide-DNA complexes that regulate transcription of pancreatic genes. This mechanism is described within the Khavinson bioregulator framework, which holds that short tissue-specific peptides act as transcriptional regulators in aged or dysfunctional tissue.
In aged pancreatic cell cultures, the peptide increased expression of transcription factors PDX1, NGN3, PAX6, FOXA2, NKX2-2, NKX6.1, and PAX4 — regulators of beta-cell development and function — as well as differentiation markers MMP2, MMP9, serotonin, and CD79alpha, with reduced apoptosis markers (Khavinson and colleagues 2013). In diabetic rat models, both oral and injectable routes produced metabolic and vascular signals (Khavinson and colleagues 2007). One biological-activity study examined the C-terminally amidated form (Lys-Glu-Asp-Trp-NH₂, KEDW-NH₂) rather than the free-acid tetrapeptide (Khavinson and colleagues 2011); whether the amidated and free-acid forms have equivalent biological activity is not resolved in the available literature.
Direct DNA binding by a tetrapeptide and the resulting pancreas-specific transcription-factor activation have not been independently validated by structural biology, chromatin immunoprecipitation, or equivalent biochemical methods outside the originating program. Mechanistic plausibility in cell systems cannot be treated as established clinical mechanism.
Open questions
- Independent replication: No human or primate study from outside the Khavinson research program has reproduced the core findings. Whether the glucose and insulin effects would replicate under independent Western controlled-trial conditions is the central unresolved question.
- Controlled human trial: The existing 33-patient study is insufficient to establish clinical efficacy for type 2 diabetes management. A larger, properly blinded and randomised controlled trial with a comparator arm and transparent methodology is absent.
- Pharmacokinetics in humans: Oral and sublingual bioavailability of the intact tetrapeptide, distribution to pancreatic tissue, and clearance have not been characterised in humans. Whether Lys-Glu-Asp-Trp survives gastrointestinal digestion as an intact peptide is not established in the available literature.
- Mechanism validation: Direct DNA binding by a tetrapeptide and the resulting tissue-specific transcription-factor activation have not been confirmed by independent structural or molecular biology methods.
- Long-term safety and proliferative risk: Cumulative repeated-course effects on pancreatic cells — including any proliferative effects relevant in subclinical malignancy contexts — have not been studied.
- Amidation equivalence: One biological-activity study (Khavinson and colleagues 2011) used the C-terminally amidated form (KEDW-NH₂). Whether the amidated and free-acid forms have equivalent activity, and which is present in commercial preparations, is not resolved.
Related peptides
Other Khavinson bioregulator tetrapeptides with published evidence: Epithalon (Ala-Glu-Asp-Gly, pineal bioregulator), Thymalin (thymic peptide complex), Pinealon (Glu-Asp-Arg, brain bioregulator). These share the same design framework and publication lineage. No related pep-IDs are linked here pending verification of platform card existence.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Is KEDW acting on the much more abundant enzyme-secreting pancreatic cells rather than the rarer insulin-producing cells?
If KEDW works mainly through digestive enzyme production, it could be useful for a completely different group of patients, including those with pancreatitis or pancreatic enzyme deficiency, and would need to be tested and dosed very differently for diabetes.
If the chemical cap on KEDW's tail is lost in the body, does it turn into the vascular peptide KED instead of acting on the pancreas?
If the cap is essential for pancreatic specificity, drug developers would need to ensure any KEDW formulation protects this feature during digestion, preventing accidental conversion to a vascular-active molecule and ensuring the peptide reaches the right organ.
▸3-letter notation
▸citationbibtex
@peptide{pep10935,
sequence = {KEDP},
target = {},
author = {peptidemodel},
year = {2026},
status = {designed}
}